CPHI’s Post

🚀 2024 Mid-Year Outlook: Navigating Global M&A Trends in Health Industries As we move into the second half of 2024, M&A remains a crucial tool to unlock value and drive innovation in the health industries. Dealmaking activity is expected to be robust, with companies adapting to elevated interest rates and regulatory pressures. 🔍 Key Insights: - Active Deal Environment: Pharmaceuticals, life sciences, and healthcare services are poised for significant M&A activity as companies seek innovative assets and review portfolios for divestiture opportunities. - Sector-Specific Trends: >> Pharmaceuticals: Expect ongoing biotech acquisitions and divestitures to offset revenue declines from lost exclusivity. >> GLP-1 Drugs: High demand is driving notable deals, such as Roche’s acquisition of Carmot Therapeutics and Novo Nordisk’s proposed acquisition of Catalent. >> Healthcare Services: Continued rollups in fragmented sectors like private clinics, specialist care, and elderly care. 📈 Outlook Ahead: Health industries companies are focusing on transforming their business models, leveraging digital capabilities, and optimizing portfolios. Strategic acquisitions and divestitures will continue to drive M&A activity, helping companies achieve their growth and innovation goals. 🔗 Read the full report to explore the detailed trends and opportunities shaping the health industries M&A landscape in 2024. https://lnkd.in/eAPksex3 Start the conversation with @Bart Vandeweyer of PwC Belgian Deals M&A practice. #MergersAndAcquisitions #HealthIndustries #Pharmaceuticals #Healthcare #PwCBelgium #2024Outlook #Innovation #DigitalHealth

🚀 2024 Mid-Year Outlook: Navigating Global M&A Trends in Health Industries As we move into the second half of 2024, M&A remains a crucial tool to unlock value and drive innovation in the health industries. Dealmaking activity is expected to be robust, with companies adapting to elevated interest rates and regulatory pressures. 🔍 Key Insights: - Active Deal Environment: Pharmaceuticals, life sciences, and healthcare services are poised for significant M&A activity as companies seek innovative assets and review portfolios for divestiture opportunities. - Sector-Specific Trends: >> Pharmaceuticals: Expect ongoing biotech acquisitions and divestitures to offset revenue declines from lost exclusivity. >> GLP-1 Drugs: High demand is driving notable deals, such as Roche’s acquisition of Carmot Therapeutics and Novo Nordisk’s proposed acquisition of Catalent. >> Healthcare Services: Continued rollups in fragmented sectors like private clinics, specialist care, and elderly care. 📈 Outlook Ahead: Health industries companies are focusing on transforming their business models, leveraging digital capabilities, and optimizing portfolios. Strategic acquisitions and divestitures will continue to drive M&A activity, helping companies achieve their growth and innovation goals. 🔗 Read the full report to explore the detailed trends and opportunities shaping the health industries M&A landscape in 2024. https://lnkd.in/evYT88kQ Start the conversation with @Bart Vandeweyer of PwC Belgian Deals M&A practice. #MergersAndAcquisitions #HealthIndustries #Pharmaceuticals #Healthcare #PwCBelgium #2024Outlook #Innovation #DigitalHealth

🚀 2024 Mid-Year Outlook: Navigating Global M&A Trends in Health Industries As we move into the second half of 2024, M&A remains a crucial tool to unlock value and drive innovation in the health industries. Dealmaking activity is expected to be robust, with companies adapting to elevated interest rates and regulatory pressures. 🔍 Key Insights: - Active Deal Environment: Pharmaceuticals, life sciences, and healthcare services are poised for significant M&A activity as companies seek innovative assets and review portfolios for divestiture opportunities. - Sector-Specific Trends: >> Pharmaceuticals: Expect ongoing biotech acquisitions and divestitures to offset revenue declines from lost exclusivity. >> GLP-1 Drugs: High demand is driving notable deals, such as Roche’s acquisition of Carmot Therapeutics and Novo Nordisk’s proposed acquisition of Catalent. >> Healthcare Services: Continued rollups in fragmented sectors like private clinics, specialist care, and elderly care. 📈 Outlook Ahead: Health industries companies are focusing on transforming their business models, leveraging digital capabilities, and optimizing portfolios. Strategic acquisitions and divestitures will continue to drive M&A activity, helping companies achieve their growth and innovation goals. 🔗 Read the full report to explore the detailed trends and opportunities shaping the health industries M&A landscape in 2024. https://lnkd.in/evrFkPw6 Start the conversation with @Bart Vandeweyer of PwC Belgian Deals M&A practice. #MergersAndAcquisitions #HealthIndustries #Pharmaceuticals #Healthcare #PwCBelgium #2024Outlook #Innovation #DigitalHealth

🚀 2024 Mid-Year Outlook: Navigating Global M&A Trends in Health Industries As we move into the second half of 2024, M&A remains a crucial tool to unlock value and drive innovation in the health industries. Dealmaking activity is expected to be robust, with companies adapting to elevated interest rates and regulatory pressures. 🔍 Key Insights: - Active Deal Environment: Pharmaceuticals, life sciences, and healthcare services are poised for significant M&A activity as companies seek innovative assets and review portfolios for divestiture opportunities. - Sector-Specific Trends: >> Pharmaceuticals: Expect ongoing biotech acquisitions and divestitures to offset revenue declines from lost exclusivity. >> GLP-1 Drugs: High demand is driving notable deals, such as Roche’s acquisition of Carmot Therapeutics and Novo Nordisk’s proposed acquisition of Catalent. >> Healthcare Services: Continued rollups in fragmented sectors like private clinics, specialist care, and elderly care. 📈 Outlook Ahead: Health industries companies are focusing on transforming their business models, leveraging digital capabilities, and optimizing portfolios. Strategic acquisitions and divestitures will continue to drive M&A activity, helping companies achieve their growth and innovation goals. 🔗 Read the full report to explore the detailed trends and opportunities shaping the health industries M&A landscape in 2024. https://lnkd.in/dxCDq2P7 Start the conversation with @Bart Vandeweyer of PwC Belgian Deals M&A practice. #MergersAndAcquisitions #HealthIndustries #Pharmaceuticals #Healthcare #PwCBelgium #2024Outlook #Innovation #DigitalHealth

🚀 2024 Mid-Year Outlook: Navigating Global M&A Trends in Health Industries As we move into the second half of 2024, M&A remains a crucial tool to unlock value and drive innovation in the health industries. Dealmaking activity is expected to be robust, with companies adapting to elevated interest rates and regulatory pressures. 🔍 Key Insights: - Active Deal Environment: Pharmaceuticals, life sciences, and healthcare services are poised for significant M&A activity as companies seek innovative assets and review portfolios for divestiture opportunities. - Sector-Specific Trends: >> Pharmaceuticals: Expect ongoing biotech acquisitions and divestitures to offset revenue declines from lost exclusivity. >> GLP-1 Drugs: High demand is driving notable deals, such as Roche’s acquisition of Carmot Therapeutics and Novo Nordisk’s proposed acquisition of Catalent. >> Healthcare Services: Continued rollups in fragmented sectors like private clinics, specialist care, and elderly care. 📈 Outlook Ahead: Health industries companies are focusing on transforming their business models, leveraging digital capabilities, and optimizing portfolios. Strategic acquisitions and divestitures will continue to drive M&A activity, helping companies achieve their growth and innovation goals. 🔗 Read the full report to explore the detailed trends and opportunities shaping the health industries M&A landscape in 2024. https://lnkd.in/eaDxcfYy Start the conversation with @Bart Vandeweyer of PwC Belgian Deals M&A practice. #MergersAndAcquisitions #HealthIndustries #Pharmaceuticals #Healthcare #PwCBelgium #2024Outlook #Innovation #DigitalHealth

Why do we see this more and more? Here are 3 reasons why: 1. It’s faster When youve got the money, buying someone else’s innovation is quicker. Time needn’t be your enemy when the shareholders come knocking. 2. It’s less risky Timelines aside, acquisitions enable Big Pharma to pick innovations that already have a track record of success. There’s less chance you’ll end up with something that doesn’t work. 3. Patents on old assets are expiring Spencer Knight and I just did a video that mentions this. Over $100B in patents are expiring for legacy Big Pharma therapeutics. They’ll need new medicines to fill the gap in revenue - so don’t expect mergers and acquisitions to stop anytime soon. So remember… When you’ve got the money, buying innovation can be faster and less rocky than doing it all yourself. Any other points you’d add? Drop them in the comments. #cellandgenetherapy #biotechnology #innovation

🚀 2024 Mid-Year Outlook: Navigating Global M&A Trends in Health Industries As we move into the second half of 2024, M&A remains a crucial tool to unlock value and drive innovation in the health industries. Dealmaking activity is expected to be robust, with companies adapting to elevated interest rates and regulatory pressures. 🔍 Key Insights: - Active Deal Environment: Pharmaceuticals, life sciences, and healthcare services are poised for significant M&A activity as companies seek innovative assets and review portfolios for divestiture opportunities. - Sector-Specific Trends: >> Pharmaceuticals: Expect ongoing biotech acquisitions and divestitures to offset revenue declines from lost exclusivity. >> GLP-1 Drugs: High demand is driving notable deals, such as Roche’s acquisition of Carmot Therapeutics and Novo Nordisk’s proposed acquisition of Catalent. >> Healthcare Services: Continued rollups in fragmented sectors like private clinics, specialist care, and elderly care. 📈 Outlook Ahead: Health industries companies are focusing on transforming their business models, leveraging digital capabilities, and optimizing portfolios. Strategic acquisitions and divestitures will continue to drive M&A activity, helping companies achieve their growth and innovation goals. 🔗 Read the full report to explore the detailed trends and opportunities shaping the health industries M&A landscape in 2024. https://lnkd.in/eF5MeqZg Start the conversation with @Bart Vandeweyer of PwC Belgian Deals M&A practice. #MergersAndAcquisitions #HealthIndustries #Pharmaceuticals #Healthcare #PwCBelgium #2024Outlook #Innovation #DigitalHealth

🚀 2024 Mid-Year Outlook: Navigating Global M&A Trends in Health Industries As we move into the second half of 2024, M&A remains a crucial tool to unlock value and drive innovation in the health industries. Dealmaking activity is expected to be robust, with companies adapting to elevated interest rates and regulatory pressures. 🔍 Key Insights: - Active Deal Environment: Pharmaceuticals, life sciences, and healthcare services are poised for significant M&A activity as companies seek innovative assets and review portfolios for divestiture opportunities. - Sector-Specific Trends: >> Pharmaceuticals: Expect ongoing biotech acquisitions and divestitures to offset revenue declines from lost exclusivity. >> GLP-1 Drugs: High demand is driving notable deals, such as Roche’s acquisition of Carmot Therapeutics and Novo Nordisk’s proposed acquisition of Catalent. >> Healthcare Services: Continued rollups in fragmented sectors like private clinics, specialist care, and elderly care. 📈 Outlook Ahead: Health industries companies are focusing on transforming their business models, leveraging digital capabilities, and optimizing portfolios. Strategic acquisitions and divestitures will continue to drive M&A activity, helping companies achieve their growth and innovation goals. 🔗 Read the full report to explore the detailed trends and opportunities shaping the health industries M&A landscape in 2024. https://lnkd.in/efufcngM Start the conversation with @Bart Vandeweyer of PwC Belgian Deals M&A practice. #MergersAndAcquisitions #HealthIndustries #Pharmaceuticals #Healthcare #PwCBelgium #2024Outlook #Innovation #DigitalHealth

🚀 2024 Mid-Year Outlook: Navigating Global M&A Trends in Health Industries As we move into the second half of 2024, M&A remains a crucial tool to unlock value and drive innovation in the health industries. Dealmaking activity is expected to be robust, with companies adapting to elevated interest rates and regulatory pressures. 🔍 Key Insights: - Active Deal Environment: Pharmaceuticals, life sciences, and healthcare services are poised for significant M&A activity as companies seek innovative assets and review portfolios for divestiture opportunities. - Sector-Specific Trends: >> Pharmaceuticals: Expect ongoing biotech acquisitions and divestitures to offset revenue declines from lost exclusivity. >> GLP-1 Drugs: High demand is driving notable deals, such as Roche’s acquisition of Carmot Therapeutics and Novo Nordisk’s proposed acquisition of Catalent. >> Healthcare Services: Continued rollups in fragmented sectors like private clinics, specialist care, and elderly care. 📈 Outlook Ahead: Health industries companies are focusing on transforming their business models, leveraging digital capabilities, and optimizing portfolios. Strategic acquisitions and divestitures will continue to drive M&A activity, helping companies achieve their growth and innovation goals. 🔗 Read the full report to explore the detailed trends and opportunities shaping the health industries M&A landscape in 2024. https://lnkd.in/eY9gZ9Gz Start the conversation with @Bart Vandeweyer of PwC Belgian Deals M&A practice. #MergersAndAcquisitions #HealthIndustries #Pharmaceuticals #Healthcare #PwCBelgium #2024Outlook #Innovation #DigitalHealth

🚀 2024 Mid-Year Outlook: Navigating Global M&A Trends in Health Industries As we move into the second half of 2024, M&A remains a crucial tool to unlock value and drive innovation in the health industries. Dealmaking activity is expected to be robust, with companies adapting to elevated interest rates and regulatory pressures. 🔍 Key Insights: - Active Deal Environment: Pharmaceuticals, life sciences, and healthcare services are poised for significant M&A activity as companies seek innovative assets and review portfolios for divestiture opportunities. - Sector-Specific Trends: >> Pharmaceuticals: Expect ongoing biotech acquisitions and divestitures to offset revenue declines from lost exclusivity. >> GLP-1 Drugs: High demand is driving notable deals, such as Roche’s acquisition of Carmot Therapeutics and Novo Nordisk’s proposed acquisition of Catalent. >> Healthcare Services: Continued rollups in fragmented sectors like private clinics, specialist care, and elderly care. 📈 Outlook Ahead: Health industries companies are focusing on transforming their business models, leveraging digital capabilities, and optimizing portfolios. Strategic acquisitions and divestitures will continue to drive M&A activity, helping companies achieve their growth and innovation goals. 🔗 Read the full report to explore the detailed trends and opportunities shaping the health industries M&A landscape in 2024. https://lnkd.in/eUNGxicv Start the conversation with @Bart Vandeweyer of PwC Belgian Deals M&A practice. #MergersAndAcquisitions #HealthIndustries #Pharmaceuticals #Healthcare #PwCBelgium #2024Outlook #Innovation #DigitalHealth